Financial factors shaping treatment decisions in oncology: A systematic review.

J Cancer PolicyJul 21, 2026 (epub)
Clinical ResearchOncology (Medical)

Ebunoluwa J Olunuga, Joshua Woo, Anagh Kulkarni et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined how financial factors influence treatment decisions in oncology, analyzing 60 studies. It found that financial incentives, particularly from industry, significantly affect prescribing behaviors, with physicians often caught between cost-conscious care and the desire to offer all beneficial therapies. The review highlights the need for systemic changes to support cost-effective oncology practices.

Key findings

  • Financial influences were identified across three domains: physician-industry, physician-patient, and physician-physician.
  • Industry payments and financial incentives were linked to increased prescribing of promoted drugs, especially with larger incentives.
  • Patient out-of-pocket costs frequently impacted treatment recommendations, though discussions about costs were less common.

Why it matters

Understanding the financial factors that shape treatment decisions is crucial for improving cost-conscious care in oncology. This knowledge can inform policy changes and support clinicians in navigating financial complexities in patient care.

Source

Published in J Cancer Policy. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.